Adalimumab biosimilar - Dong-A ST/Meiji Seika Pharma

Drug Profile

Adalimumab biosimilar - Dong-A ST/Meiji Seika Pharma

Alternative Names: DA-3113; DMB-3113

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A Pharmaceutical; Meiji Seika Pharma
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in European Union (Parenteral)
  • 01 Jan 2017 Meiji Seika Pharma completes a phase I trial in Rheumatoid arthritis (In volunteers) in Japan (SC) (NCT02927353)
  • 01 Aug 2016 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in Japan (SC) (JapicCTI-163390)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top